Leflunomide – 25 mg

Brand:
Cayman
CAS:
75706-12-6
Storage:
-20
UN-No:
De Minimis - 2811 / 6.1

Leflunomide is a synthetic isoxazol and a prodrug form of A-771726 (Item No. 14404), a dihydroorotate dehydrogenase inhibitor.{22723} Leflunomide inhibits de novo pyrimidine synthesis to regulate T lymphocyte progression through the cell cycle. It inhibits proliferation and activation of T cells when used at concentrations of 25 and 100 µM, respectively, for naïve and memory CD4+ T cells.{46073} It also reduces the production of Th1 effector cells and increases differentiation of Th2 cells in vitro and in splenocytes isolated from KLH-immunized mice. Leflunomide (35 mg/kg per day) reduces and prevents inflammation in a proteoglycan-induced mouse model of rheumatoid arthritis.{46074} Formulations containing leflunomide have been used in the treatment of active rheumatoid arthritis.  

 

SKU: - Category:

Description

A prodrug form of A-771726; inhibits de novo pyrimidine synthesis to regulate T lymphocyte progression through the cell cycle; inhibits proliferation and activation of T cells at 25 and 100 µM, respectively, for naïve and memory CD4+ T cells; reduces and prevents inflammation in a proteoglycan-induced mouse model of rheumatoid arthritis at 35 mg/kg per day


Formal name: 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide

Synonyms:  Arava|HW 486|SU 101

Molecular weight: 270.2

CAS: 75706-12-6

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Nucleic Acid Turnover/Signaling||Research Area|Immunology & Inflammation|Adaptive Immunity||Research Area|Immunology & Inflammation|Autoimmunity|Rheumatoid Arthritis||Research Area|Immunology & Inflammation|Immunosuppressants||Research Area|Immunology & Inflammation|Innate Immunity